Vasoconstrictor Potential of Coronary Aspirate From Patients Undergoing Stenting of Saphenous Vein Aortocoronary Bypass Grafts and Its Pharmacological Attenuation

Rationale: Stent implantation into atherosclerotic plaques releases, apart from particulate debris, soluble substances that contribute to impaired microvascular perfusion. Objective: To quantify the release of vasoconstrictors and to determine the efficacy of coronary dilators to attenuate their action. Methods and Results: Using a distal protection/aspiration device, coronary arterial blood was retrieved before and during stenting in 22 patients with severe saphenous vein aorto-coronary bypass stenoses. The release of catecholamines, endothelin, serotonin, thromboxane B2, and tumor necrosis factor (TNF)&agr; was measured. The response of rat mesenteric arteries with intact (+E) and denuded (−E) endothelium to aspirate plasma was normalized to that by KCl. Responses to selective receptor blockade, adenosine, nitroprusside, and verapamil against the aspirate-induced constriction were determined. The coronary arterial plasma withdrawn before stenting induced 21±5% and the aspirate plasma after stenting induced 95±8% of maximum KCl-induced vasoconstriction. Serotonin, thromboxane B2, and TNF&agr; release into aspirate plasma increased by 1.9±0.2 &mgr;mol/L, 25.6±3.1 pg/mL, and 19.7±6.1 pg/mL, respectively, during stenting. The aspirate-induced vasoconstriction was largely antagonized by selective serotonin receptor blockade, with little further antagonism by additional thromboxane receptor blockade. TNF&agr; did not induce constriction per se but potentiated the constriction with serotonin and the thromboxane-analog U-46619 in arteries +E. The concentrations to induce half-maximal vasodilation were comparable for nitroprusside (+E, 3.3×10−8; −E, 1.9×10−8 mol/L) and verapamil (+E, 8.3×10−8; −E, 7.8×10−8 mol/L), and the vasoconstriction was eventually eliminated. The vasodilator response to adenosine was dependent on functional endothelium and weaker. Conclusion: Serotonin is the main coronary vasoconstrictor after stenting, and thromboxane and TNF&agr; somewhat potentiate the serotonin response. Nitroprusside and verapamil are more potent than adenosine to attenuate the aspirate plasma-induced vasoconstriction, and they are not dependent on functional endothelium.

[1]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[2]  F. Van de Werf,et al.  High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. , 2011, European heart journal.

[3]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[4]  G. Heusch,et al.  TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. , 2010, Pharmacology & therapeutics.

[5]  P. Ferdinandy,et al.  Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. , 2010, Cardiovascular research.

[6]  S. Frisbee,et al.  Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. , 2010, Physiological genomics.

[7]  A. Kastrati,et al.  5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. , 2010, Journal of the American College of Cardiology.

[8]  R. Virmani,et al.  Microvascular obstruction: underlying pathophysiology and clinical diagnosis. , 2010, Journal of the American College of Cardiology.

[9]  Xiangbin Xu,et al.  Direct relationship between levels of TNF-α expression and endothelial dysfunction in reperfusion injury , 2010, Basic Research in Cardiology.

[10]  R. Erbel,et al.  Coronary microembolization: from bedside to bench and back to bedside. , 2009, Circulation.

[11]  A. Iskandrian,et al.  Pretreatment with nitroprusside for microcirculatory protection in saphenous vein graft interventions. , 2009, The Journal of invasive cardiology.

[12]  G. Heusch Adenosine and maximum coronary vasodilation in humans: myth and misconceptions in the assessment of coronary reserve , 2009, Basic Research in Cardiology.

[13]  Michael Weis,et al.  Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. , 2008, European heart journal.

[14]  Raimund Erbel,et al.  Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions , 2008, Basic Research in Cardiology.

[15]  R. Jaffe,et al.  Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous Coronary Intervention , 2008, Circulation.

[16]  A. Balduini,et al.  Tissue Factor in Patients with Acute Coronary Syndromes. Expression In , 2022 .

[17]  A. Feldman,et al.  TNF-&agr; Contributes to Endothelial Dysfunction by Upregulating Arginase in Ischemia/Reperfusion Injury , 2007 .

[18]  R. Erbel,et al.  Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis. , 2007, American journal of physiology. Heart and circulatory physiology.

[19]  A. Maseri,et al.  Frequency of slow coronary flow following successful stent implantation and effect of Nitroprusside. , 2007, The American journal of cardiology.

[20]  G. Maurer,et al.  Active endothelin is an important vasoconstrictor in acute coronary thrombi , 2007, Thrombosis and Haemostasis.

[21]  A. Feldman,et al.  TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[22]  M. de Belder,et al.  Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes , 2006, Heart.

[23]  E. Romagnoli,et al.  Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. , 2006, European heart journal.

[24]  R. Erbel,et al.  Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. , 2006, Journal of the American College of Cardiology.

[25]  N. Weissman,et al.  Comparison of ruptured plaques in native coronary arteries and in saphenous vein grafts: an intravascular ultrasound study. , 2006, The American journal of cardiology.

[26]  L. Kuo,et al.  TNF-&agr; Contributes to Endothelial Dysfunction in Ischemia/Reperfusion Injury , 2005 .

[27]  J. Herrmann Peri-procedural myocardial injury: 2005 update. , 2005, European heart journal.

[28]  A. Jacobs,et al.  Aspirin resistance and atherothrombotic disease. , 2005, Journal of the American College of Cardiology.

[29]  V. Pasceri,et al.  Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. , 2005, The American journal of cardiology.

[30]  Takashi Saito,et al.  Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. , 2005, American journal of physiology. Heart and circulatory physiology.

[31]  M. Hersberger,et al.  Inflammatory Markers at the Site of Ruptured Plaque in Acute Myocardial Infarction: Locally Increased Interleukin-6 and Serum Amyloid A but Decreased C-Reactive Protein , 2005, Circulation.

[32]  M. Hori,et al.  Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts. , 2004, Journal of molecular and cellular cardiology.

[33]  H. Figulla,et al.  Intracoronary verapamil for reversal of no‐reflow during coronary angioplasty for acute myocardial infarction , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[34]  C. Gibson,et al.  Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. , 2002, The Journal of invasive cardiology.

[35]  G. Maurer,et al.  Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. , 2002, Blood.

[36]  S. Sdringola,et al.  Risk assessment of slow or no‐reflow phenomenon in aortocoronary vein graft percutaneous intervention , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[37]  F. Cipollone,et al.  Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.

[38]  M. Kern,et al.  The coronary no-reflow phenomenon: a review of mechanisms and therapies. , 2001, European heart journal.

[39]  G. Caughey,et al.  Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: Implications for the Use of Cyclooxygenase Inhibitors1 , 2000, The Journal of Immunology.

[40]  Y. Boie,et al.  The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. , 2000, Biochimica et biophysica acta.

[41]  F. Rengo,et al.  Intracoronary serotonin release after high-pressure coronary stenting. , 1999, The American journal of cardiology.

[42]  T. Branchek,et al.  Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. , 1999, European journal of pharmacology.

[43]  C. White,et al.  Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina. , 1998, American heart journal.

[44]  Katherine C. Wu,et al.  Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. , 1998, Circulation.

[45]  S. Hourani,et al.  Activation of two sites by adenosine receptor agonists to cause relaxation in rat isolated mesenteric artery , 1997, British journal of pharmacology.

[46]  W. O’Neill,et al.  Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. , 1996, Catheterization and cardiovascular diagnosis.

[47]  Y. Nishimura Characterization of 5‐hydroxytryptamine receptors mediating contractions in basilar arteries from stroke‐prone spontaneously hypertensive rats , 1996, British journal of pharmacology.

[48]  M. Condorelli,et al.  Local effect of serotonin released during coronary angioplasty. , 1994, The New England journal of medicine.

[49]  M. Yacoub,et al.  Interaction Between Thromboxane A2 and 5‐Hydroxytryptamine Receptor Subtpes in Human Coronary Arteries , 1993, Circulation.

[50]  W. Roberts,et al.  Comparison of composition of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary arteries in the same men. , 1992, The American journal of cardiology.

[51]  G. Heusch Myocardial stunning: a role for calcium antagonists during ischaemia? , 1992, Cardiovascular research.

[52]  M. Yanagisawa,et al.  The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Jessup,et al.  Studies In The Guinea‐pig With ICI 185,282: A Thromboxane A2 Receptor Antagonist , 1988, The Journal of pharmacy and pharmacology.

[54]  R. Frye,et al.  Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. , 1987, Journal of the American College of Cardiology.

[55]  E. Braunwald,et al.  Effect of verapamil on infarct size in dogs subjected to coronary artery occlusion with transient reperfusion. , 1986, Journal of the American College of Cardiology.

[56]  G. FitzGerald,et al.  11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[57]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[58]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[59]  E. Watson Liquid chromatography with electrochemical detection for plasma norepinephrine and epinephrine. , 1981, Life sciences.

[60]  M. Mulvany,et al.  The active tension-length curve of vascular smooth muscle related to its cellular components , 1979, The Journal of general physiology.

[61]  M. Mulvany,et al.  Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. , 1977, Circulation research.

[62]  R. Kloner,et al.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog. , 1974, The Journal of clinical investigation.